cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors
- Graeme B Bolger1,2⇑,
- Mariana F Bizzi3,
- Sergio V Pinheiro4,
- Giampaolo Trivellin5,
- Lisa Smoot1,
- Mary-Ann Accavitti6,
- Márta Korbonits5,* and
- Antonio Ribeiro-Oliveira Jr3,*
- 1Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
- 2Department of Pharmacology, University of Alabama at Birmingham, Birmingham, Alabama, USA
- 3Department of Internal Medicine, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
- 4Department of Pediatrics, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
- 5Center for Endocrinology, William Harvey Research Institute, Barts and The London School of Medicine, Queen Mary University of London, London, UK
- 6Department of Microbiology and Immunology, University of Alabama at Birmingham, Birmingham, Alabama, USA
- Correspondence should be addressed to G B Bolger; Email: gbbolger{at}uab.edu
Abstract
PDE4 cyclic nucleotide phosphodiesterases regulate cAMP abundance in cells and therefore regulate numerous processes, including cell growth and differentiation. The rat PDE4A5 isoform (human homolog PDE4A4) interacts with the AIP protein (also called XAP2 or ARA-9). Germline mutations in AIP occur in approximately 20% of patients with Familial Isolated Pituitary Adenoma (FIPA) and 20% of childhood-onset simplex somatotroph adenomas. We therefore examined the protein expression of PDE4A4 and the closely related isoform PDE4A8 in normal human pituitary tissue and in pituitary adenomas. PDE4A4 had low expression in normal pituitary but was significantly overexpressed in somatotroph, lactotroph, corticotroph and clinically nonfunctioning gonadotroph adenomas (P<0.0001 for all subtypes). Likewise, PDE4A8 was expressed in normal pituitary and was also significantly overexpressed in the adenoma subtypes (P<0.0001 for all). Among the different adenoma subtypes, corticotroph and lactotroph adenomas were the highest and lowest expressed for PDE4A4, respectively, whereas the opposite was observed for PDE4A8. Naturally occurring oncogenic variants in AIP were shown by a two-hybrid assay to disrupt the ability of AIP to interact with PDE4A5. A reverse two-hybrid screen identified numerous additional variants in the tetratricopeptide repeat (TPR) region of AIP that also disrupted its ability to interact with PDE4A5. The expression of PDE4A4 and PDE4A8 in normal pituitary, their increased expression in adenomatous pituitary cells where AIP is meant to participate, and the disruption of the PDE4A4–AIP interaction by AIP mutants may play a role in pituitary tumorigenesis.
- Received 31 March 2016
- Accepted 18 April 2016
- Made available online as an Accepted Preprint 1 May 2016
- © 2016 Society for Endocrinology